FDA approves Genentech Enspryng as first at-home subcutaneous treatment for thyroid eye disease
The FDA has approved Genentech's Enspryng as the first at-home subcutaneous treatment option for adults with thyroid eye disease.
Enspryng (satralizumab-mwge), an interleukin-6 receptor inhibitor, can be administered subcutaneously with maintenance dosing every four weeks, expanding its use beyond its previously authorised indication.
The approval was supported by Phase III SatraGO-1 and SatraGO-2 studies, which provided evidence of improvements in eye bulging and double vision among patients with thyroid eye disease.
Field | Content |
Article Type | Approvals |
Drug Name | Enspryng |
Generic Name | Satralizumab-mwge |
Company | Genentech |
Parent Company | Roche |
Regulatory Authority | U.S. Food and Drug Administration |
Regulatory Decision | Expanded indication approval |
Approval Date | 15 October 2026 |
New Indication | Thyroid eye disease in adults |
Patient Population | Adults with thyroid eye disease |
Therapeutic Area | Ophthalmology; autoimmune inflammatory disease |
Drug Class | Interleukin-6 receptor inhibitor |
Mechanism of Action | IL-6 receptor inhibition |
Administration Route | Subcutaneous injection |
Administration Setting | At-home administration |
Maintenance Dosing | Every four weeks |
Supporting Clinical Studies | Phase III SatraGO-1 and SatraGO-2 |
Reported Clinical Outcomes | Improvements in eye bulging and double vision |
Approval Significance | First FDA-approved at-home subcutaneous treatment option for thyroid eye disease |
Previous Indication | Previously approved for another indication; details not specified in supplied summary |
Geography | United States |
What Happened | The FDA expanded Enspryng's approval to include adults with thyroid eye disease. |
Why It Matters | The approval introduces an at-home injectable treatment option for a condition that can cause substantial visual and functional impairment. |
Clinical Evidence | Phase III SatraGO-1 and SatraGO-2 studies supported the decision; specific efficacy percentages were not provided in the supplied summary. |
Potential Impact | At-home administration and four-week maintenance dosing may offer greater treatment flexibility for eligible patients. |
Key Takeaway | Enspryng is now FDA-approved for adult thyroid eye disease as an at-home subcutaneous treatment. |
What to Watch | US commercial availability, reimbursement, physician adoption, patient experience and longer-term treatment outcomes. |
Primary Source | Genentech |
Primary Source URL | https://www.gene.com/media/news-features/fda-approves-first-in-class-il-6r-inhibitor-as-the-first-and-only-at-home-subcutaneous-treatment-option-for-thyroid-eye-disease-ted |
Relevant Date | 15 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comentários